With the progressive aging of the world's population, osteoporosis has emerged as an important global health problem. Based on population growth and the current incidence of hip fractures in Asia, it is estimated that by 2050 50% of the world's hip fractures will occur in Asian women \[[@CR1]\].

Bisphosphonates are regarded as the treatment of choice for postmenopausal osteoporosis and have proven clinical benefits, including a significantly reduced risk of vertebral and nonvertebral fractures in many clinical trials \[[@CR2]--[@CR6]\]. However, adherence to treatment among patients with postmenopausal osteoporosis is currently suboptimal, like in other chronic diseases \[[@CR7], [@CR8]\]. Poor adherence leads to reduced clinical benefit, a raised incidence of secondary complications, and therefore increased health-care costs \[[@CR7]\]. Data from a study evaluating adherence to bisphosphonate therapy show that the probability of continuing daily oral treatment is approximately 50% at 1 year \[[@CR9]\]. This problem is largely contributed to the complex and inconvenient dosing instructions due to their low bioavailability and the potential for upper gastrointestinal (GI) side effects \[[@CR8]\].

Patient treatment preference is an important factor in determining patient satisfaction with medical care and could provide an efficient way of maximizing the effectiveness of medical care \[[@CR10]\]. Patient preferences for daily or weekly bisphosphonate therapy have been evaluated in prospective, open-label studies \[[@CR11], [@CR12]\]. Actually, numerous studies have proven that weekly dosing improves therapeutic adherence, though it remains suboptimal \[[@CR13]--[@CR15]\].

Ibandronate is a potent, new aminobisphosphonate with proven antifracture efficacy \[[@CR2]\] and can be administered as a monthly regimen. A comparative study (Monthly Oral Iandronate in Ladies study \[MOBILE\]) demonstrated that monthly ibandronate was as effective and well tolerated as the currently approved daily ibandronate regimen in postmenopausal osteoporosis \[[@CR6]\]. Furthermore, two randomized, multicenter clinical trials (the Bonviva Alendronate Trial in Osteoporosis \[BALTO I and II\]) found that significantly more women with postmenopausal osteoporosis preferred the monthly oral ibandronate regimen than the weekly alendronate regimen \[[@CR16], [@CR17]\]. However, it is difficult to apply this result in Asian countries because both studies had populations that were only about 1% Asian. Moreover, there has been no randomized multicenter clinical trial comparing patient preference between ibandronate and risedronate, which is also widely prescribed for the treatment of osteoporosis. In addition, there were few studies comparing bone turnover markers between ibandronate and risedronate.

This study was aimed at determining whether the preference results of Caucasians are similar to those of Koreans. Other objectives were comparison of preference, convenience, and bone turnover marker between monthly ibandronate and weekly risedronate.

Methods {#Sec1}
=======

Study Design {#Sec2}
------------

This was a 6-month, prospective, randomized, open-label, multicenter, two-period, and two-sequence crossover study to investigate patient preference on dosing between once-monthly ibandronate and once-weekly risedronate. The study design was similar to that used in previous studies (BALTO I and II) \[[@CR16], [@CR17]\] except that this study compared ibandronate with risedronate, not alendronate, and measured serum C-telopeptide of type I collagen (CTX) of participants both at baseline and 12 weeks after treatment to examine the change in bone turnover.

The study was conducted between March 2007 and May 2008 in 15 centers in South Korea and enrolled ambulatory women with postmenopausal osteoporosis who were bisphosphonate-naive. Participants were required to be able to understand and complete the Preference Questionnaire and to comply with the study protocol to be enrolled in this study. Women with upper GI disease such as reflux esophagitis uncontrolled with drugs or delayed esophageal emptying or active gastric/duodenal ulcer and who were unable to maintain an upright position for at least 60 minutes were excluded. Subjects who had hypersensitivity to ibandronate or risedronate; any other metabolic bone diseases but postmenopausal osteoporosis; any chronic diseases which could affect bone metabolism; or any abnormalities in laboratory parameters such as serum calcium, liver, or kidney function test and had been taking glucocorticoid were also excluded. All participants provided informed consent. The appropriate independent ethics committee or institutional review board approved the study protocol and all materials provided to participants.

After a 30-day screening period, eligible participants were randomized to take either monthly oral ibandronate 150 mg (Bonviva; F. Hoffmann-La Roche Ltd, Basel, Switzerland) for 3 months followed by weekly oral risedronate 35 mg (Actonel; Sanofi-Aventis Korea, Seoul, Korea) for 12 weeks (sequence A) or the same regimen in reverse order (sequence B) (Fig. [1](#Fig1){ref-type="fig"}). Central randomization was used to ensure similar distribution between the two sequences. There was no washout period between the two treatment regimens. The crossover in treatment regimens occurred after 3 months' treatment with ibandronate (sequence A) or 12 weeks' treatment with risedronate (sequence B). Additional safety information was collected 15 days after the end of treatment. Participants were educated to take both study medications in the morning after an overnight fast (6 hours or more), to keep an upright position (sitting or standing), and not to eat or drink fluids other than water for either 60 minutes or 30 minutes after taking ibandronate or risedronate, respectively. All participants received appropriate dosing and administration instructions and were reminded by telephone contact before each medication dosing schedule (ibandronate every month, risedronate every week). All women were supplemented with daily elemental calcium 500 mg and vitamin D 125 IU (Oscal 500 D; Handok Pharmaceuticals, Seoul, Korea). Compliance was estimated by recording drugs dispensed versus drugs returned on the case record form. Adverse events and laboratory parameters were assessed by the study investigators. The use of clinically relevant concomitant medications was also recorded.Fig. 1Study design and randomization schedule

The primary end point of this study was patients' preference. The secondary end points were convenience and bone turnover marker level.

Preference Questionnaire {#Sec3}
------------------------

All participants were asked to answer the Preference Questionnaire at the end of the study (month 6) or when they withdrew from the study. The Preference Questionnaire was adapted from the BALTO I and II \[[@CR16], [@CR17]\]. If patients withdrew from the study before the crossover point, i.e., after having taken only the first treatment in the sequence, they were not requested to complete the questionnaire. If they withdrew after taking at least one dose of the second treatment in the sequence, they were asked to complete the questionnaire at the time of withdrawal. Patients were asked to complete the questionnaire by themselves before any other scheduled procedure at the visit and were not assisted in completing the questionnaire.

Bone Turnover Marker {#Sec4}
--------------------

Serum levels of CTX were measured at baseline and after 3 months of treatment. Blood samples for CTX assessments were taken at the end of the dosing interval (1 month after 3-month dosing of ibandronate, one week after 12-week dosing of risedronate), after an overnight fast of at least 6 hours, between 8:00 a.m. and 10:00 a.m., and processed at the central laboratory (Green Cross Reference Lab, Seoul, Korea). CTX levels were measured by electrochemiluminescence immunoassay (Modular Analytics, E170 Modular; Roche, Mannheim, Germany).

Statistical Analysis {#Sec5}
--------------------

The significance of preference and convenience was assessed, accounting for the potential effect of treatment order, using Gart's test \[[@CR18]\] (excluding subjects with no preference) and Prescott's test \[[@CR19]\] (including all preference and no preference data). Baseline and 3-month serum CTX levels between the two groups were analyzed with Student's *t*-test. The mean percentage changes in serum CTX (3 months -- baseline values) between the two sequences were tested with ANCOVA and 95% confidence interval. All the tests were two-sided, with a significance level of *P* \< 0.05.

Results {#Sec6}
=======

Patient Disposition and Baseline Characteristics {#Sec7}
------------------------------------------------

A total of 365 women were enrolled in this study; 182 were randomized to sequence A and 183 to sequence B. The safety population (defined as patients who had received at least one dose of trial medication and had follow-up data end point) comprised 352 women included in the modified intention-to-treat population (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Disposition of subjects

Participants in sequence A and sequence B were well matched for age as well as weight, height, time since menopause, and time since diagnosis of postmenopausal osteoporosis (Table [1](#Tab1){ref-type="table"}). There were no significant differences between sequences A and B in prior fragility fracture, family history of fragility fracture in a first-degree relative, and current smoking. The most common medications received by patients prior to study enrollment for the treatment of osteoporosis were estrogen and progestin (sequence A 34.5%, sequence B 34.7%).Table 1Patient demographics (safety population)VariableSequence A (*n* = 176)Sequence B (*n* = 176)Total (*n* = 352)Age (years) Mean61.362.061.7 Range48--7946--7846--79Height (cm) Mean154.3154.6154.5 Range143--174141--170141--174Weight (kg) Mean55.555.955.7 Range37--7636--8136--81Highest educational level Elementary school47 (26.7%)51 (29.0%)98 (27.8%) Middle/high school96 (54.6%)73 (41.5%)169 (48.0%) College/university10 (5.7%)17 (9.7%)27 (7.7%) Postgraduate degree0 (0.0%)1 (0.6%)1 (0.3%) Unknown23 (13.1%)34 (19.3%)57 (16.2%)Current occupation Working31 (17.6%)27 (15.3%)58 (16.5%) Not working145 (82.4%)149 (84.7%)294 (83.5%)Fracture history Yes37 (21.0%)34 (19.3%)71 (20.2%)Sequence A: monthly ibandronate → weekly risedronateSequence B: weekly risedronate → monthly ibandronate

Preference {#Sec8}
----------

Most women (262/314, 83.4%) preferred one of the two regimens to the other. Of the patients who reported a preference, 74.8% (196/262) preferred the monthly regimen of ibandronate and 25.2% (66/262) preferred the weekly regimen of risedronate. The preference rate for monthly ibandronate was statistically significant (*P* \< 0.0001). Preference for monthly ibandronate was not affected by the order in which the women took the study medications (Gart order-effect *P* = 0.6210). When data from all patients were included, i.e., including women who did not express a preference, 62.4% (196/314) preferred monthly ibandronate dosing and 21.0% (66/314) preferred weekly risedronate dosing (Fig. [3](#Fig3){ref-type="fig"}). Again, the preference rate for monthly ibandronate was statistically significant (*P* \< 0.0001).Fig. 3Patient preferences for ibandronate monthly dosing over risedronate weekly dosing, including patients who did not express a preference for one treatment

The reasons identified by patients for their preference are detailed in Fig. [4](#Fig4){ref-type="fig"} (patients could choose more than one reason). Of the 74.8% of participants who expressed a preference for the monthly ibandronate regimen, 77.6% (152/196) chose the greater ease of long-term adherence and 52.6% (103/196) a better lifestyle fit as a reason for their preference. The proportions of participants who mentioned less stomach discomfort and more easily tolerated side effects were 24.0% (47/196) and 22.0% (43/196), respectively.Fig. 4Patient preferences and reasons for preference (excluding patients who did not state a preference for one treatment). Patients could provide more than one reason for preferring a particular regimen

Convenience {#Sec9}
-----------

Of the women expressing an opinion on convenience (229/314, 72.9%), 84.2% found that the monthly ibandronate regimen was more convenient and 15.8% (43/272) found that the weekly risedronate regimen was more convenient. The convenience rate for monthly ibandronate dosing was statistically significant (*P* \< 0.0001). This opinion was not affected by treatment sequence (Gart order-effect, *P* = 0.8814). Similar results were shown when the analysis included patients who did not express an opinion about treatment convenience (Fig. [5](#Fig5){ref-type="fig"}): The monthly ibandronate regimen was chosen by 72.9% of the overall study population and the weekly risedronate regimen was chosen by 13.7%. Again, the convenience rate for monthly ibandronate was statistically significant (*P* \< 0.0001).Fig. 5Patients who found ibandronate monthly dosing more convenient than risedronate weekly dosing, including patients who did not express an opinion about convenience for one treatment

Compliance {#Sec10}
----------

The compliance rate of the monthly ibandronate group was significantly higher than that of the weekly risedronate group (*P* \< 0.01). The difference in compliance was relatively prominent at month 6 compared to month 3 (Table [2](#Tab2){ref-type="table"}).Table 2Compliance with study medicationIbandronate *n* (%)Risedronate *n* (%)Total *n* (%)*P* (exact test)Month 3 0--\<50%3 (1.9)1 (0.6)4 (1.3)0.0018 50--\<100%1 (0.6)12 (7.7)13 (4.1) 100%153 (97.5)144 (91.7)297 (94.6) Total157 (50.0)157 (50.0)314 (100.0)Month 6 0--\<50%1 (0.6)3 (1.9)4 (1.3)\<0.0001 50--\<100%1 (0.6)19 (12.1)20 (6.4) 100%155 (98.7)135 (86.0)290 (92.3) Total157 (50.0)157 (50.0)314 (100.0)

Bone Turnover Marker {#Sec11}
--------------------

There was no statistically significant difference between the monthly and weekly bisphosphonate groups in baseline and 3-month serum CTX levels. In addition, there was no statistical significant difference between the two treatment groups in mean percent change of serum CTX values (Table [3](#Tab3){ref-type="table"}).Table 3Changes in biochemical bone marker serum CTXSerum CTX (ng/mL)IbandronateRisedronate*P* (*t*-test)Baseline* n*153154 Mean ± SD0.54 ± 0.260.50 ± 0.230.1861 Range0.04--1.630.12--1.62Month 3* n*153155 Mean ± SD0.21 ± 0.160.20 ± 0.150.4788 Range0.02--0.970.03--0.70Percent change* n*153154 Mean ± SD--57.23 ± 35.89--56.95 ± 37.070.9456 Range--96.28--172.41--92.96--172.78

Safety {#Sec12}
------

The incidence of adverse events was comparable between the two bisphosphonate regimens, with 41.0% and 40.1% of patients experiencing at least one event during ibandronate and risedronate treatment, respectively. Treatment-related adverse events were reported by 29.5% of patients during ibandronate treatment and 29.9% of patients during risedronate treatment. Treatment-related GI adverse events were reported by 19.4% of patients while taking ibandronate and 23.1% of patients while taking risedronate. More patients receiving once-weekly risedronate experienced abdominal distension and nausea (6.9% vs. 3.3% and 6.9% vs. 3.0%, respectively; *P* \< 0.05). Other frequent adverse events were generally comparable between patients receiving ibandronate and risedronate (Table [4](#Tab4){ref-type="table"}). The incidence of adverse events resulting in withdrawal from the study was 4.2% (*n* = 14) in patients receiving ibandronate and 4.5% (*n* = 15) in patients receiving risedronate. Clinically relevant changes in laboratory parameters were not observed in any patient during the study.Table 4Summary of most frequent adverse events (AE)Ibandronate (*n* = 336, %)Risedronate (*n* = 334, %)*P* (χ^2^ test)Gastrointestinal AE65 (19.4)77 (23.1)0.2402 Dyspepsia25 (7.4)24 (7.2)0.8992 Abdominal distension11 (3.3)23 (6.9)0.0332 Nausea10 (3.0)23 (6.9)0.0194 Abdominal pain10 (3.0)5 (1.5)0.1957 Abdominal pain upper6 (1.8)9 (2.7)0.4266 Gastroesophageal reflux7 (2.1)7 (2.1)0.9910Musculoskeletal AE63 (18.8)50 (15.0)0.1914 Myalgia46 (13.7)43 (12.9)0.7556 Arthralgia6 (1.8)5 (1.5)0.7687Nervous system AE17 (5.1)18 (5.4)0.8479 Headache8 (2.4)6 (1.8)0.5969 Dizziness7 (2.1)5 (1.5)0.5672

Discussion {#Sec13}
==========

Although bisphosphonates are regarded as the treatment of choice for postmenopausal osteoporosis, their poor adherence and persistence have limited their efficacy. It was known that patients preferred less frequent, simpler, and more convenient dosing regimens \[[@CR20], [@CR21]\]. A weekly dosing regimen has better therapeutic adherence than a daily dosing regimen in postmenopausal osteoporosis; however, it remains suboptimal \[[@CR13]--[@CR15]\]. Ibandronate is a potent, nitrogen-containing bisphosphonate which has been approved in Europe, the United States, and Korea to be given as a monthly regimen. The BALTO I and II studies reported that more women with postmenopausal osteoporosis preferred the monthly ibandronate regimen and expressed that the monthly ibandronate was more convenient than the weekly alendronate regimen \[[@CR16], [@CR17]\]. However, these findings cannot be applied in Asian countries because the participants in these studies included only about 1% Asian ethnicity. Furthermore, there have been few studies about preferences between monthly ibandronate and weekly risedronate, which have comparable efficacy and tolerability in treatment of osteoporosis \[[@CR22]--[@CR24]\]. This study has not only reconfirmed previous findings from the BALTO studies in Korea, an Asian country, but also proved that monthly ibandronate had better preference and convenience than weekly risedronate, similar to Western results, which was highly expected despite the different ethnicity.

One of the main reasons for noncompliance is the occurrence of adverse events \[[@CR25]\]. In this study, the overall incidence of adverse events was similar between the two bisphosphonate regimens. The number of patients who were withdrawn from the study because of adverse events was also similar in both treatments. These results were also consistent with the previous BALTO studies.

Clinical trials evaluating the GI tolerability of bisphosphonates have found no significant differences in the incidence of spontaneously reported GI adverse events between placebo and bisphosphonates \[[@CR2], [@CR4], [@CR26]\]. However, GI adverse symptoms have been reported with bisphosphonate use in the clinical setting and may be an important factor for discontinuing treatment \[[@CR27]--[@CR30]\]. BALTO I and II reported that the patients receiving both the monthly ibandronate and weekly alendronate regimens experienced similar GI adverse events. In this study, more patients receiving once-weekly risedronate experienced abdominal distension and nausea, though other GI adverse events occurred similarly in both treatments.

In many clinical studies, monthly ibandronate showed a significant increase in bone mineral density (BMD) and a reduction in fracture risk \[[@CR2], [@CR6], [@CR31]\]. Once-monthly ibandronate was shown to be clinically comparable to weekly alendronate at increasing BMD after 12 months in both the lumbar spine and total hip \[[@CR32]\]. Furthermore, a retrospective cohort study found that patients treated with oral monthly ibandronate or weekly bisphosphonates (alendronate and risedronate) had similar low risks of hip fracture, nonvertebral fracture, and any clinical fracture. Ibandronate patients had a significantly lower relative risk of vertebral fracture than weekly bisphosphonate patients \[[@CR33]\]. However, there were few studies comparing the change in bone turnover marker after treatment with monthly ibandronate and weekly bisphosphonates. In the present study, although it was of relatively short duration, both treatment regimens showed a similar percentage change of bone turnover marker.

Recently, a study reported that the monthly ibandronate regimen showed a better persistence rate with therapy than the weekly regimen, even though telephone contact was provided only to the monthly ibandronate group \[[@CR34]\]. This study was not designed to assess the persistence of treatment. Further studies on monthly ibandronate persistence will be required in Asian countries.

In conclusion, this study confirmed the patient preference for monthly ibandronate over weekly bisphosphonates in Korean. Moreover, the present study indicates that the results previously reported vs. alendronate are also applicable to risedronate. Monthly ibandronate showed similar reduction of bone turnover marker compared to a weekly regimen. Patients with a monthly ibandronate regimen experienced fewer upper GI adverse events (nausea, abdominal distension) in this study.
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